Vivek Subbiah

Dr. Vivek Subbiah, M.D., is an associate professor in the Investigational Cancer Therapeutics department (a Phase 1 program). He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division, at The University of Texas MD Anderson Cancer Center.

After completing his medical school in India at Sri Ramachandra Medical College and Research Institute, India he completed a combined residency in Internal Medicine and Pediatrics at Case Western Reserve University, MetroHealth, Cleveland Ohio. Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatrics and has completed fellowships in both adult and pediatric oncology at MD Anderson.

Dr. Vivek Subbiah is a clinical trialist and Physician Investigator in the Department of Investigational Cancer Therapeutics at MD Anderson, which is the largest oncology drug development unit in the world. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a specialist interest in anti-body drug conjugates, radio-pharmaceuticals, immunoconjugates and basket trials. Dr. Subbiah serves as the Principal Investigator in numerous trials, certainly leaving an accomplished impression on the national and international drug development community. Dr. Subbiah has skillfully led the MD Anderson effort on the international Vemurafenib Basket Trial in non-melanoma BRAF V600-mutated cancers, which pioneered a novel histology-independent clinical trial design. Vemurafenib was FDA approved in Erdheim-Chester disease based on this trial. Dabrafenib and trametinib was U.S. FDA-approved in the treatment of BRAF V600-mutant anaplastic thyroid cancer (ATC) based on practice changing data from the Rare Oncology Agnostic Approach (ROAR) trial lead by Dr. Subbiah. Furthermore, his novel investigator-initiated trials have also laid the foundation for therapeutic breakthroughs for additional rare cancers. Specifically, his clinical trial for Radium-223 as a treatment for relapsed osteosarcoma was singularly responsible for the inclusion of this radiopharmaceutical in the treatment algorithm of osteosarcoma in the guidelines of the National Comprehensive Cancer Network (NCCN).

Dr. Subbiah is a major advocate for precision oncology. His national leadership roles continue to expand as the National PI for the BRAF non-V600 alteration arm of the NCI-MATCH Precision Medicine Clinical Trial. His trial portfolio includes trials that target BRAF, MEK, RET, CDK, WNT, VEGF,mTOR, EZH2-EED pathways, novel immunotherapy combination trials GITR, TLR7/9, PD1, WT1, several first-in-human antibody drug conjugates, oncolytic viruses, intra-tumoral therapies and radiopharmaceuticals. He has published over 150 peer-reviewed in several prestigious journals such as the New England Journal of Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Clinical Cancer Research, and Lancet Oncology.

Louis M. Staudt

Dr. Staudt received his B.A. from Harvard College in 1976 and his M.D.-Ph.D. degrees in 1982 from the University of Pennsylvania School of Medicine in 1982. Following Internal Medicine training, he joined Nobel Laureate David Baltimore's laboratory at the Whitehead Institute as a Jane Coffin Childs Fellow.

In 1988, he established his laboratory at the National Cancer Institute (NCI), which now focuses on the molecular basis for human lymphoid malignancies and the development of new targeted therapies for these cancers.

Dr. Staudt initiated the use of genomic-scale gene expression profiling to define the molecular basis of therapeutic response and survival in lymphoid malignancies. This effort revealed that the most common aggressive form of lymphoma, diffuse large B-cell lymphoma (DLBCL), is comprised of several molecularly distinct diseases with different responses to chemotherapy. His laboratory identified the B cell receptor-dependent NF-kB pathway as a therapeutic target in the ABC molecular subtype of DLBCL, which is the least curable with current therapy. Dr. Staudt and colleagues demonstrated that inhibition of B cell receptor signaling with the BTK inhibitor ibrutinib can induce remissions in ABC DLBCL and that the addition of ibrutinib to chemotherapy significantly improves the survival of younger patients with ABC DLBCL.

At the National Cancer Institute, Dr. Staudt serves as Chief of the Lymphoid Malignancies Branch and Director of the Center for Cancer Genomics. He has received numerous awards for his research, including the Dameshek Prize for outstanding contribution in hematology (American Society of Hematology), the San Salvatore Prize for the treatment of malignant tumors, the C. Chester Stock Award Lectureship (Memorial Sloan Kettering Cancer Center), and the Princess Takamatsu Memorial Lectureship (American Association for Cancer Research – AACR). He has been elected to the AACR Academy, the National Academy of Medicine, and the National Academy of Sciences.

René Bernards

Prof. René Bernards is a professor of molecular carcinogenesis at the Netherlands Cancer Institute in Amsterdam.

His laboratory uses functional genomic approaches to find vulnerabilities of cancers that can be exploited therapeutically. His laboratory identified the now FDA approved combination of a BRAF inhibitor and an EGFR inhibitor as effective for the treatment of BRAF mutant colon cancer. He also developed the first clinically used gene expression test for early breast cancer prognosis: MammaPrint, which has helped over 150,000 women in making the right treatment decision.

His current work focusses on exploiting senescence for the treatment of cancer. Amongst his honors are the Pezcoller Foundation award, the Ernst Bertner Award for Cancer Research from the M.D. Anderson Cancer Center and the ESMO Lifetime Achievement Award. He is also a member of the Royal Netherlands Academy of Sciences, the National Academy of Sciences, the American Academy of Arts and Sciences and a fellow of the AACR Academy.

Andrea Califano

Dr. Andrea Califano is the Clyde and Helen Wu Professor of Chemical and Systems Biology at Columbia University Irving Medical Center, the Founding Chair of the Department of Systems Biology, and Director of the JP Sulzberger Columbia Genome Center. He also holds appointments in the Departments of Biochemistry & Molecular Biophysics, Biomedical Informatics, and Medicine.

He was originally trained as a physicist and has applied physics-based approaches, including extensive use of information theory principles, to the reverse engineering and interrogation of gene regulatory networks to systematically and efficiently identify key tumor checkpoint modules, whose aberrant activity is necessary for tumor viability. This has resulted in several clinical trials, including a very innovative N-of-1 study for precision cancer medicine.

Dr. Califano has received several awards and recognitions, including the NCI Outstanding Investigator Award; Fellow of the AAAS, and of the NY Academy of Medicine and Academy of Science; and Member of the National Academy of Medicine. He is also the Co-founder of DarwinHealth Inc.

Richard L. Schilsky

Dr. Richard L. Schilsky earned his M.D. at the University of Chicago Pritzker School of Medicine in 1975. Following a residency in Internal Medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in Medical Oncology and Clinical Pharmacology at the National Cancer Institute (NCI) from 1977 to 1981. Dr. Schilsky returned to the University of Chicago in 1984 where he rose to the rank of Professor of Medicine (tenured) and served as Director of the University of Chicago Cancer Research Center (1991-99), as Associate Dean for Clinical Research (1999-2007) and as Chief of the Section of Hematology-Oncology (2009-2012). An international expert in gastrointestinal malignancies and cancer pharmacology Dr. Schilsky served as Chairman of the Cancer and Leukemia Group B, an NCI-sponsored national cancer clinical trials group from 1995-2010.

Dr. Schilsky has served on a number of peer review and advisory committees for the National Cancer Institute (NCI) including as a member and chair of the NCI Board of Scientific Advisors and as a member of the Clinical and Translational Research Advisory Committee. He has also served as a member and chair of the Oncologic Drugs Advisory Committee of the Food and Drug Administration. He presently serves as a member of the Board of Directors of the Reagan-Udall Foundation for the FDA, a member of the Board of Directors of Friends of Cancer Research and as a member of the National Cancer Policy Forum of the Institute of Medicine. Dr. Schilsky has served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO), ASCO President 2008-2009 and ASCO Executive Vice President and Chief Medical Officer(2013-2021).

Dr. Schilsky is Chairman of the WIN Consortium.

Enriqueta Felip

Prof. Enriqueta Felip, MD, Phd is the Co-director of Vall d’Hebron Institute of Oncology, VHIO’s Clinical Research Program, Group Leader of VHIO’s Thoracic Tumors & Head and Neck Cancer Group, Barcelona, Spain.

Prof. Felip received her medical degree from the Autonomous University of Barcelona (UAB), where she also completed her PhD studies in medical oncology. She has been Associate Professor at the UAB from 2010 to May 2019. She is nowadays, Professor of Medicine at the Universitat de Vic (UVicc-UCC). She is involved in the training of medical students, residents and particularly in mentoring fellows.

Prof. Felip is currently the President of the Spanish Society of Medical Oncology (SEOM) 2021-2023. Dr Felip is member of the Scientific Committee of the Spanish Lung Cancer Group (SLCG).

Prof. Felip is now President of the Oncology Comission at Vall d’Hebron University Hospital and she is as member of the Scientific Advisory Committee of the Parc Taulí Sabadell Hospital.

Prof. Felip has been involved in several initiatives with scientific organizations, among them, as Subject Editor of Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer and Coordinator of the 1st ESMO Consensus Conference in lung cancer. Dr. Felip has been Co-chair of the 20th WCLC Congress that took place last September 2019 in Barcelona. Dr. Felip receives the 1st ESMO Women for Oncology Award in 2015. She is at present member of the Scientific Committee of the European Thoracic Oncology Platform.

Prof. Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

Sabine Tejpar

Prof. Sabine Tejpar, Ph.D. serves as an Associate Professor in the Dept of Gastro Enterology, Digestive Oncology Unit, UZ Leuven. Prof. Tejpar works as a part time clinician, part time researcher (Senior Clinical Investigator of the Fund for Scientific Research- Flanders (Belgium)), with a focus on basic and translational research in colorectal cancer.

Prof. Tejpar's main research projects involve prognostic markers in adjuvant colorectal cancer and predictive markers for efficacy of EGFR inhibition. Prof. Tejpar has published over fifty peer-reviewed publications and is a member of the EORTC, active in Board Gastrointestinal Group; member of the EORTC PAMM and Laboratory Research Division and Co-Chair of the EORTC-NCI-ASCO tutorial sessions. She is a member of advisory board of several pharmaceutical companies in relation to new drug development and translational research in gastrointestinal cancer.

Prof. Tejpar is trained in Internal medicine and Gastro Enterology and holds a Ph.D in the program of Molecular Oncology at the Center for Human Genetics, KULeuven.

Fabrice André

Professor Fabrice André, MD, PhD, received his MD in Grenoble in 2002, and a PhD in Biotechnology from Paris University in 2005.

He is a medical oncologist working at Gustave Roussy and taking care of patients with breast cancer. He is a past recipient of Career Development Awards from the American Society of Clinical Oncology (ASCO) and Outstanding Investigator in Breast Cancer Award from the American Association for Cancer Research (AACR). He is currently Head of Research Division, and Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.

His research work in the field of biomarkers and personalized therapies focuses on biomarker discovery, development of targeted agents and implementation of personalized medicine. His team includes 80 people working on basic sciences, bioinformatics, biotechnologies and clinical research. He is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system.

Professor André has published more than 300 peer reviewed papers, including papers in Nature, the New England Journal of Medicine, Lancet, Nature Medicine, as main author.
Professor André is chairman of the biomarker group at UNICANCER (French cooperative group) and was a member of several scientific committees for international meetings, including SABCS, AACR, ECCO, ESMO, and IMPAKT. Professor André has been a member of the Annals of Oncology Editorial Board (2010-2013), Associate Editor since 2014 and in September 2017 became Editor-in-Chief.

Professor Fabrice André, Director of Research at Gustave Roussy, has been elected to the 2025-2026 presidency of the European Society for Medical Oncology (ESMO).

Olivier Elemento

Dr. Olivier Elemento, PhD is a professor of physiology and biophysics at Weill Cornell Medicine (WCM) and Cornell University. Since 2017, he has been Director of the Caryl and Israel Englander Institute for Precision Medicine, a multidisciplinary institute that draws on more than 100 faculty members from nearly all basic and clinical departments at Cornell University. Its mission is to use genomics, artificial intelligence (AI) and other technologies to develop and bring highly personalized medicine to patients at WCM’s affiliated hospital, NewYork-Presbyterian Hospital (NYPH), and elsewhere. The institute also fosters patient-centered basic and clinical research in the areas of genomics, systems biology, AI and data science.

Olivier Elemento is funded by numerous NIH grants, foundation grants, NIH contracts and industry alliances. He has published more than 330 articles in the areas of precision medicine, genomics, computational biology, AI, systems biology and drug discovery. He has led the development of novel clinical genomics assays, including whole-exome sequencing offered to patients at WCM and NYPH, and is currently leading a large multidisease effort to bring whole-genome sequencing into clinical practice at WCM and NYPH. He co-founded two venture capital-funded companies: Volastra Therapeutics (with Lew Cantley and Sam Bakhoum) and OneThree Biotech (with Neel Madhukar). He serves on the scientific advisory boards of Volastra, OneThree Biotech, Owkin, Freenome and several other companies.

John Quackenbush

Prof. John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, Professor in the Channing Division of Network Medicine, and Professor at the Dana-Farber Cancer Institute.

John’s PhD was in Theoretical Physics, but in 1992 he received a fellowship to work on the Human Genome Project. This led him through the Salk Institute, Stanford, The Institute for Genomic Research (TIGR), and to Harvard in 2005. John uses massive data to probe how many small effects combine to influence human health and disease.

He has more than 300 scientific papers and over 73,000 citations. Among his honors is recognition in 2013 as a White House Open Science Champion of Change.

Vladimir Lazar

Dr. Vladimir Lazar obtained his MD (1989) at The University of Timisoara (Romania), First Class and Certificate of Merit. He became a Specialist in Medical Clinical Biology and obtained his PhD in molecular biology (1997) at The University René Descartes in Paris, with the highest degree and the Prize of University. He was the Head of Gustave Roussy’s Genomic Center and Integrated Biology Platform (2002-2015); Dr Vladimir Lazar, M.D, Ph.D. is specialized in clinical biology, molecular biology, molecular pathology and has a broad training, education and postgraduate degrees in biotechnology (first in class) and project management.

He is author of 8 patents and author-co-author of more than 100 publications. He is the Founder of the WIN Consortium and is the Chief Scientific and Operating officer.

Eytan Ruppin

Dr. Eytan Ruppin, MD and PhD (Computer Science) has served as a professor of Computer Science & Medicine at Tel-Aviv University (Israel) and Director of the University of Maryland Computational and Bioinformatics Center, before joining the NCI as the Chief of its newly established Cancer Data Science Lab.

His research focuses on developing and harnessing novel computational systems biology approaches, first in computational neuroscience and in recent years, on the multi-omics analysis of cancer. He collaborates with many experimental cancer labs, aiming to utilize computational approaches to jointly gain a network-level integrative view of the systems we study, and predict and test novel drug targets and biomarkers to treat cancer more selectively and effectively.

His lab has identified the first metabolic synthetic lethal (SL) drug target to treat cancer in a joint experimental/computational effort [1] and has been the first to identify SL networks in cancer in a genome-wide manner from TCGA analysis [2]. Together with his experimental collaborators, they have developed a new approach for stratifying patients for immunotherapy treatment [3] and discovered a fundamental link between urea cycle dysregulation, mutational bias and response to immunotherapy [4]. His main focus in recent years have been on developing a new approach for SL-based precision-based cancer therapy [5], which is now moving into clinical prospective testing.

Josep Tabernero

Dr. Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology. He is highly involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies. He is especially devoted to phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, such as the EGFR-family and IGF-1R, the PI3K and ERK signalling pathways, as well as downstream cytoplasmatic and intranucleous effectors including Mdm2/p53 and aurora kinase. Based on the idea that each tumor has an independent genetic identity, his own research group, Gastrointestinal & Endocrine Tumors, actively participates in the development of molecular therapies targeting specific oncoproteins, aimed at developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1-R among others) for those patients displaying genetic lesions or pathway disregulation. One of group´s key goals is to identify new predictive markers of response to diverse treatments and unmask markers of primary resistance (de novo) and secondary treatment. At preclinical level, his group is involved in developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

He is past President of the European Society for Medical Oncology (ESMO)(2018 – 2019) and an Executive Board Member. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and has been appointed as member of several Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.

Dr. Tabernero is Vice-Chairman of the WIN Consortium and Chairman of the Scientific Advisory Board (SAB).

Jean-François Martini

Dr. Jean-François Martini has biotech and pharma industry experience in pharmacology and clinical translational sciences and is author/coauthor of over 50 scientific publications. He is currently Executive Director, Translational Oncology, Global Product Development-Oncology and has been at Pfizer, in La Jolla, California, for the past 10 years. He was previously Sr. Director, Translational Medicine, at Exelixis, So San Francisco, California, where he contributed to the approval of cobimetinib and cabozantinib, and to projects such as the alliance with Sanofi for the PI3K programs and out-licensing of esaxerenone to Daiichi Sankyo.

He completed his postdoctoral training at University of California, San Francisco, where he studied the antiangiogenic properties of fragments of Prolactin and Growth Hormone, after obtaining a PhD in Biochemistry and Molecular Biology from University of Paris XI, France. At Pfizer, he currently leads and/or supports the translational strategy for the cell cycle modulators (CDK inhibitors); the Renal Cell Cancer franchise (sunitinib, axitnib); and lorlatinib (ALK/ROS1 inhibitors) in Lung Cancer. He also leads the cross functional efforts in the area of liquid biopsy/cfDNA (represents Pfizer as part of Blood Profiling Atlas-Cancer; Friends of Cancer Research) and is the Pfizer board of director representative for the WIN consortium.

Benjamin Solomon

Dr. Benjamin Solomon, M.D, is a medical oncologist and at Avera Cancer Institute, in Sioux Falls, SD.

Dr. Solomon holds two administrative directorships as the Medical Information Officer and the Oncology Clinical Research Officer at Avera. He graduated from University of Nebraska Medical Center prior to completing residency in internal medicine and fellowship in medical oncology and hematology at Mayo Clinic, in Rochester, MN. His clinical practice focuses on diagnosis and management of patients with solid tumors.

Dr. Solomon’s current research focuses on applied precision oncology approaches to the treatment of lung cancer.

Amir Onn

Prof. Amir Onn is a graduate of the Hadassah and Hebrew University School of Medicine in Jerusalem, Israel. He completed his residency in internal medicine and fellowship in pulmonary medicine at the Tel-Aviv Sourasky Medical Center, affiliated with Tel Aviv University. He continued with his post-doctoral fellowship and a clinical fellowship in interventional pulmonary oncology at the University of Texas MD Anderson Cancer Center.

He then became a member of the faculty of the department of pulmonary medicine at MDACC and as an assistant professor received a physician scientist grant. Since his return to Israel in 2006, Prof. Onn has developed the pulmonary oncology service and became the Chair, Institute of Pulmonary Medicine at the Sheba Medical Center. In addition, he is a co-director of the institutional tumor bank, and the program director of the Sheba Medical Center and MDACC sister institution program.

In 2011, he initiated and chaired the first Israeli multidisciplinary conference on lung cancer and he is the chair of this annual meeting. His areas of research interest are lung cancer genomics and the biology of pleural effusion.

Prof. Onn is WIN Head of Standard Operating Procedures and Repository Committee

Haiquan Chen

Prof. Haiquan Chen, Professor & Chairman, Department of Thoracic Surgery, Team Leader, Thoracic Oncology MDT, Director, Lung Cancer Center, Fudan University Shanghai Cancer Center.

International Academic Association: Active Member of the American Association for Thoracic Surgery (AATS)(2011- ) ,Member of the Membership Committee (AATS) (2016-2017) , AATS Focus Faculty (2013-2016), AATS Focus on Thoracic Surgery: CHINA 2016 Co-Chair and AATS 2016 Annual Meeting General Thoracic Skill Co-Chair, Member of the Society of Thoracic Surgeons (STS) (2004- ), Member of the Workforce on International Relationships (STS)(2011-2013, 2014-2016), International Member of the Board of Directors of the Society of Thoracic Surgeons (STS) (2016-2019), Fellow of the American College of Chest Physicians (FCCP), Member of the European Society of Thoracic Surgeons (ESTS) (2015-), Council Member of Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) (2016-). Vice Chairman, Chinese Association of Thoracic Surgeons; Vice Chief Committee Member, Shanghai Association of Cardiothoracic Surgery; Chief Committee Member, Thoracic Oncology Committee of Shanghai Anticancer Society.

Vice Chief Editor: Journal of Cancer Research, Clinical Oncology.

Editorial Board member: Journal of Thoracic and Cardiovascular Surgery, Journal of Cancer Research and Clinical Oncology, Journal of Thoracic Disease, American Journal of Translational Research.

Prof. Chen has gained a lot of financial support from NSFC and Shanghai Science and Technology Committee program. In last 5 years, over 150 articles were published in peer-review academic journal like Cancer Cell, JCO, CCR, ANN SURG, Cancer, JTCVS, ANN THORAC SURG. In addition, three novel methods for detecting fusion genes have gained national patent of invention. In 2012, Prof. Chen was awarded Shanghai Outstanding Academic Leader, after sequential awards from the science and technology prize of CACA (rank 1)，Shanghai Science and Technology Development Prize (rank1,2,3), Huaxia Medical Science and Technology Prize(rank 1), Chinese Medical Science and Technology Prize(rank 1), Military Medical Achievements Prize (rank 1), Shanghai Medical Science and Technology Prize (rank 2)，The third national famous doctor "outstanding building title.

Research Focus: Translational research of molecular and biological markers in lung cancer

Jair Bar

Dr. Jair Bar, MD., PhD. Deputy Director, Cancer Center, and the Head of the Thoracic Oncology Unit, Sheba Medical Center. Dr. Bar has started his specialization in Oncology (Chemotherapy and Radiotherapy) at the Sheba Medical Center, then he was a clinical fellow in Thoracic Oncology at The Ottawa Hospital Cancer Centre.

Dr. Bar is the recipient of the Dr. Lawrence Kline/Ms. Sherry Merkis Award. He was a part of the initiative group to establish the Israel Lung Cancer Group (ILCG), and is a Chair of ILCG since 2003. Dr. Bar is also a member of ISCORT, ASCO and AACR.

He is an author of numerous articles and chapters in medical literature.

Pilar Garrido

Dr. Pilar Garrido is Associate Professor of Medical Oncology at Universidad de Alcalá (Madrid, Spain) and serves as Head of the Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain. Co-director of the Cancer and Chronic Disease Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), her main areas of research and clinical interest are thoracic tumours, in particular multimodality management, predictive biomarkers, immunotherapy and new anticancer agents in lung cancer. Dr. Garrido is in charge of teaching and patients care and is also actively involved in a number of phase I-III lung cancer clinical trials. Active member of CiberOnc, a Spanish Ministry of Health Network of clinical and translational research, she is building a translational program in collaboration with other clinical and experimental biology Spanish cancer groups. Author of several peer-reviewed manuscripts and book chapters, she has presented her work nationally and internationally.

President of FACME (Spanish Federation of Medical Societies), she was the first woman President of the Spanish Medical Oncology Society. She currently participates on a variety of national scientific committees and is engaged with Spanish National Political and Administrative Institutions. Dr. Garrido is a member of the Spanish National Cancer Strategy Committee, former President of the Minister of Health advisory council and the Medical Oncology Specialty Training Committee.

Member of the ESMO Council and Chair of the Women for Oncology Committee, she also serves as a member of the ESMO Fellowship Committee, Press and Media Affairs Committee and the Leadership Generation Task Force. She is also Associate Editor of Annals of Oncology and a member of the ESMO Faculty for lung and other thoracic tumours. She is also Associate Editor of Annals of Oncology and a member of the ESMO Faculty for lung and other thoracic tumors. Member of the Educational Committee and the Women In Thoracic Oncology committee of the International Association for the Study of Lung Cancer (IASLC), she also participates in the American Society Clinical Oncology Congress Educational Committee.

Razelle Kurzrock

Dr. Razelle Kurzrock, MD is a world-renowned physician-scientist leader in precision medicine as well as in the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy. She is also one of the pioneering trialists of the WINTHER precision medicine trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the WIN international consortium (Nature Medicine).

During her time at the University of California San Diego Health, Dr. Kurzrock’s charge was leading the Center for Personalized Cancer Therapy as well as the Experimental Therapeutics program, and she also founded a Rare Tumor Clinic focused on precision medicine. The signature study of the center was the IPREDICT study (Nature Medicine, 2019; Genome Medicine 2021) that gave, for the first time, individualized matched combination therapies to patients with lethal malignancies, hence resulting in improved outcomes.

Dr. Kurzrock has almost 900 publications on Pubmed, an H-index of 129, and has been named to the list of most cited scientists worldwide (Web of Science) and to the list of the 25 most important voices in Precision Medicine globally.

She has four children and three dogs and lives with her husband Dr Philip Cohen, in San Diego, California.

Dr. Kurzrock is Chief Medical Officer of the WIN Consortium.

Gerald Batist

Dr. Gerald Batist is the former Chairman of the Department of Oncology at McGill University and Director of the McGill Centre for Translational Research in Cancer. A major award from the Canadian Foundation for Innovation led to the expansion of the Centre and it’s integration into the Segal Cancer Centre at the Jewish General Hospital, which he also directs.

Dr. Batist is a clinician-scientist, trained in medical oncology and molecular pharmacology. His work, both in his lab and clinical research focuses on therapeutic resistance. This includes large consortia of biopsy-based clinical trials. In 2014 he co-led a successful application that resulted in the establishment of the Canadian National Centre of Excellence in Personalized Medicine, Exactis Innovations. The core feature is a program to build a massive bio bank and database linked to a prospective longitudinal registry of cancer patients followed throughout the trajectory of their illness, a project called ‘Personalize My Treatment’.

In 2016, Dr Batist was appointed Member of the Order of Canada and Knight of the National Order of Quebec.

Matthew Ellis

Dr. Matthew Ellis is the Senior Vice President of Early Oncology research at AstraZeneca and leads a global community of over 1000 scientists working to bring the next wave of oncology medicines from target identification and into the clinic. Before joining AstraZeneca in March 2022, Matthew served as the Director for the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, USA, where he led an interdisciplinary team focused on understanding the molecular basis of breast cancer.

Matthew’s research interests lie in the application of precision medicine, proteogenomics and clinical investigation to discover the next wave of innovative medicines. Matthew’s research is documented by over 350 highly-cited publications in peer-reviewed journals including Nature, Cell, Cancer Cell, Cancer Research and Cancer Discovery.

Christophe Le Tourneau

Prof. Christophe Le Tourneau, M.D, PhD. is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic.

Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007. He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology.

Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 140+ peer-reviewed papers in international journals.

Birgit Geoerger

Dr. Birgit Geoerger, M.D, PhD is a pediatric oncologist heading the Pediatric Early Drug Development Program in the Department of Pediatric and Adolescent Oncology at Gustave Roussy Cancer Center in Villejuif, France. Dr. Geoerger is a key opinion leader in childhood cancer drug development and chaired the Clinical Trial Committee of the Innovation Therapies for Children with Cancer (ITCC) Consortium during 11 years.

She has initiated the MAPPYACTS profiling program and the AcSé-ESMART molecularly guided precision medicine therapeutic platform trial, both sponsored by Gustave Roussy, and is coordinating the pediatric relapse indication of the France Medécine Génomique 2025 program. She had developed and contributed to multiple early clinical, first-in-child and first-in-class trials. Her laboratory group in the INSERM U1015 research laboratory aims at developing new therapies for pediatric cancers.

She has authored more than 130 peer-reviewed publications.

Wafik El-Deiry

Prof. Wafik El-Deiry, MD, PhD, FACP is a practicing physician-scientist who sees patients with colorectal cancer and rare cancer-susceptibility disorders. He is a translational oncology investigator interested in cell death and drug resistance, new drugs, and precision oncology.

Prof. El-Deiry is an American Cancer Society Professor, Director of the Legorreta Cancer Center at Brown University, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, and Director of Joint Program in Cancer Biology at Brown and Lifespan. He is Professor of Pathology and Laboratory Medicine, and Mencoff Family University Professor of Medical Science at Brown. Prof.  El-Deiry discovered p21(WAF1) as p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. He discovered TRAIL receptor DR5 and its regulation by p53, and ONC201/TIC10 as TRAIL pathway, integrated stress response inducer and cancer therapeutic that has efficacy in diffuse midline gliomas and other tumor types.

He has >400 peer-reviewed publications and 5 edited books. In 2022 his H-index is 121 and he has >90,000 citations in Google Scholar.

Prof. El-Deiry founded three companies, Oncoceutics, that was acquired by Chimerix, p53-Therapeutics, and SMURF-Therapeutics. He received the inaugural Inventor of the Year Award from Brown University in 2022.

Ulrik Lassen

Ulrik Lassen, Professor, MD, Ph.D., is specialized in internal medicine and medical oncology. He graduated from the University of Copenhagen in 1991 and started training in medical oncology in 1992. In 1998 he achieved the Ph.D. degree on a thesis on PET imaging in oncology, and he was ESMO board certified in medical oncology in 2003.

Ulrik Lassen was president of the Danish Association for Cancer Research 2011-2014, and from 2013-2016 he served as president of the Danish Society of Clinical Oncology (DSKO). In 2015 he was appointed Professor in Clinical Oncology at the University of Copenhagen, with focus on precision medicine.

In 2005 Ulrik Lassen established the Phase I Unit at the Department of Oncology at Rigshospitalet. In 2014, the Phase 1 Unit, in collaboration with the Centre for Genomic Medicine, initiated a comprehensive program for Integrative Cancer Genomics (the Copenhagen Prospective Personalized Oncology (CoPPO) project), where cancer patients are selected for personalized medicine. The patients undergo a comprehensive genomic analysis, employing whole genome (WGS) and RNA-sequencing in combination with expression and SNP array analyses to unravel copy number
variations. Based on the integrated information, a complete map of somatic mutations and alterations in gene expression patterns are derived to select the most optimal treatment. More than 2000 patients have been enrolled, and more than 300 patients are every year sequenced to incorporate precision medicine in early phase trials. At present time more than 40 phase 1 trials in solid tumors and hematological malignancies are active in collaboration with major pharmaceutical companies and biotech.

Since February 2017 Ulrik Lassen has also served as head of Department of Oncology at Rigshospitalet, one of the largest oncology departments in Denmark with 600 employees, including 80 physicians.

Maria Vieito

Dr. Maria Vieito, MD, MSc is a medical oncologist who gained her MD from the University of Santiago de Compostela in 2007 and finished her specialist training in the Clinical University Hospital of the same city in 2012. After a fellowship in clinical research at the same hospital and being awarded a European Society of Medical Oncologist Fellowship in research in palliative care she completed a two-year Translational Research Fellowship awarded by the Spanish Society of Medical Oncology in London Ontario from 2013 to 2015.

Since 2017 Dr. Vieito has held a joint appointment as a medical oncologist specialized in Neuroncology in the Vall de Hebron University Hospital and as clinical investigator in the early drug development of the Vall de Hebron Institute of Oncology (VHIO).

She is an active member of the Spanish society for Neuroncology (GEINO) where she leads the Tumors in adolescents in Young adults working group and the European Organisation for Research and Treatment of Cancer (EORTC) where she is a member of the Pathobiology of cancer and the SPECTA comittees.

She is the author of 19 indexed papers as well as 12 oral comunications to international meetings.